title

MDedge Cardiocast

MDedge

2
Followers
460
Plays
MDedge Cardiocast
MDedge Cardiocast

MDedge Cardiocast

MDedge

2
Followers
460
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

MDedge Cardiocast is the weekly podcast from Cardiology News. The information in this podcast is provided for informational and educational purposes only.

Latest Episodes

Statins tied to skin, soft tissue infections; new Card Talk episode

Statin use linked to risk of skin and soft tissue infections Use of statins was associated with increased risk of SSTIs at an average of 91, 182, and 365 days. Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists. HHS floats Stark/anti-kickback revisions to support value-based care Health law attorneys say reforms should remove some of the risk in value-based care arrangements that exist under current law. * * * Card Talk: Cardiologist brothers Jim and Jerry Dwyer welcome Jennifer N. Avari Silva, MD, and Berk Tas, to talk about an investigational system for electrophysiology procedures that displays holograms of patients’ anatomies in real time. The SentiAR system uses an augmented-reality head-mounted display that allows physicians to manipulate the data and enhance their understanding of the case. Dr. Avari Silva, MD, is assistant professor of pediatrics at Washington University in St. Louis and director of pediatric cardiac electrophysiology at St. Louis Children’s Hospital, where she leads the largest pediatric electrophysiology program in the midwest. Dr. Avari Silva has published numerous papers bringing new technologies to pediatric patients. Berk Tas is CEO and president of SentiAR. He has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

41 MIN2 d ago
Comments
Statins tied to skin, soft tissue infections; new Card Talk episode

Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis

Novel cardiac troponin protocol rapidly rules out MI Three-quarters of patients who presented with suspected acute coronary syndrome were safely discharged from ED without hospital admission. Study questions preemptive TEVAR for extended type A dissections Interim results from a single-center study show that preemptive TEVAR may not be necessary for type A aortic dissections. TAVR, SAVR share same infective endocarditis risk Be aware, be careful, and provide appropriate antibiotic prophylaxis, just as surgeons do in SAVR. Moderate aortic stenosis just as deadly as severe AS The current echocardiographic definition of moderate aortic stenosis may greatly underestimate risk. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

8 MIN1 w ago
Comments
Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis

Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk

Smoking and inactivity are the most powerful lifestyle risk factors after an MI Insufficient activity beats out obesity or above-target LDL cholesterol. Ticagrelor monotherapy tops DAPT for high-risk PCI patients TWILIGHT findings support move to shorter dual-antiplatelet therapy. Panel releases guidelines for red meat, processed meat consumption "This assessment may be excessively pessimistic; indeed, we hope that is the case." Remember that preeclampsia has a ‘fourth trimester’ Delivering the baby doesn’t always cure the hypertension. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

8 MIN2 w ago
Comments
Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk

Cardiology dead last as women’s IM subspecialty choice

Cardiology dead last as women’s IM subspecialty choice Women in internal medicine residencies were more likely than men to report that they had never considered cardiology as a career choice. Beta-blockers effective, safe for HFrEF with renal dysfunction Their role is solidified for essentially all such heart failure patients, regardless of their renal function. Heart failure score derived from machine learning predicts risk in diabetes patients Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%. Daily polypill lowers BP, cholesterol in underserved population The regimen’s simplicity and low cost may overcome barriers to treatment. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

7 MIN3 w ago
Comments
Cardiology dead last as women’s IM subspecialty choice

An antiplatelet surprise; Europeans go low in cholesterol guidelines

Prasugrel bests ticagrelor in ACS in surprise findings ISAR-REACT 5 was the first-ever direct head-to-head look at two potent P2Y12 inhibitors in this setting. European cholesterol guidelines push LDL targets below 55 mg/dL PCSK-9 inhibitors are elevated to a top-tier recommendation in very-high-risk patients. Drug doses for heart failure could possibly be halved for women Women reached the highest level of drug efficacy at half the doses of ACE inhibitors or ARBs and beta-blockers. Post-MI angina in stable patients flags high risk The angina finding should immediately influence practice, expert says. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

9 MINSEP 20
Comments
An antiplatelet surprise; Europeans go low in cholesterol guidelines

SGLT-2 inhibitors and more practice changing data from ESC 2019

MDedge reporters discuss the latest in practice-changing data from the 2019 annual congress of the European Society of Cardiology in Paris. Join Mitchel L. Zoler, Bruce Jancin, Kari Oakes, and MDedge Cardiology editor Catherine Hackett as they discuss what they reported from the annual meeting.

22 MINSEP 16
Comments
SGLT-2 inhibitors and more practice changing data from ESC 2019

Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment

We introduce a brand new format with Jerome Dwyer, MD, brother of our host, Jim Dwyer, MD, for a new segment that we're calling 'Card Talk' where Dr. Jim and Dr. Jerry talk about the current clinical state of cardiology and take a peek into the future. This week in cardiology news: Survival at ‘overweight’ BMI surpasses ‘normal’Data from more than 142,000 middle-aged people worldwide show those with a BMI of 25-29 outlast those at 20-24. Visceral fat linked to sixfold increase in masked hypertensionThe body mass index trend was not significant. New class of drug safely halved LDL cholesterol in ORION-11Inclisiran potently cut LDL cholesterol by inhibiting the PCSK9 enzyme with biannual injections.

40 MINSEP 13
Comments
Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment

Dapgliflozin transomrs into heart failure drug

DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the drug as a major agent for treating heart failure. New hypertension cases halved with community-wide salt substitution Social marketing principles achieved near-universal salt replacement, village by village, in rural Peru. Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy. In PAD, dropping statins ups death risk 43% Statin adherence saves lives in peripheral arterial disease.

9 MINSEP 6
Comments
Dapgliflozin transomrs into heart failure drug

CV cost of smoking lasts a quarter century

This week in cardiology: PCSK9 inhibition cuts events in very-high-risk groups ODYSSEY OUTCOMES analyses peg prior CABG and polyvascular disease as targets for alirocumab. Cardiovascular cost of smoking may last up to 25 years Past smokers face an elevated cardiovascular risk for up to 25 years after they quit. Impact of climate change on mortality underlined by global study This may be the largest study ever to assess the effects of inhalable particulate matter around the world. HCV coinfection adds to the cardiovascular risk in HIV-infected patients Hepatitis C virus and other injections were independently linked to the risk of having a cardiovascular event in HIV-infected patients. You can contact the MDedge Cardiocast by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.

7 MINAUG 30
Comments
CV cost of smoking lasts a quarter century

Two FDA approvals, smoking impacts CV health for 25 years

TAVR valves now FDA approved for low-risk patients The FDA's decision will expand TAVR access to younger, healthier patients. FDA approves baroreflex activation for advanced HF A phase 4 trial will investigate impact on hospitalizations and mortality. Top line results: Dapagliflozin meets primary endpiont in DAPA-HF AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor. Cardiovascular cost of smoking may last up to 25 years Past smokers face an elevated cardiovascular risk for up to 25 years. You can contact the MDedge Cardiocast by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.

8 MINAUG 23
Comments
Two FDA approvals, smoking impacts CV health for 25 years

Latest Episodes

Statins tied to skin, soft tissue infections; new Card Talk episode

Statin use linked to risk of skin and soft tissue infections Use of statins was associated with increased risk of SSTIs at an average of 91, 182, and 365 days. Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists. HHS floats Stark/anti-kickback revisions to support value-based care Health law attorneys say reforms should remove some of the risk in value-based care arrangements that exist under current law. * * * Card Talk: Cardiologist brothers Jim and Jerry Dwyer welcome Jennifer N. Avari Silva, MD, and Berk Tas, to talk about an investigational system for electrophysiology procedures that displays holograms of patients’ anatomies in real time. The SentiAR system uses an augmented-reality head-mounted display that allows physicians to manipulate the data and enhance their understanding of the case. Dr. Avari Silva, MD, is assistant professor of pediatrics at Washington University in St. Louis and director of pediatric cardiac electrophysiology at St. Louis Children’s Hospital, where she leads the largest pediatric electrophysiology program in the midwest. Dr. Avari Silva has published numerous papers bringing new technologies to pediatric patients. Berk Tas is CEO and president of SentiAR. He has led development of emerging technologies and companies in Fortune 500, private equity, venture capital funded and privately held organizations. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

41 MIN2 d ago
Comments
Statins tied to skin, soft tissue infections; new Card Talk episode

Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis

Novel cardiac troponin protocol rapidly rules out MI Three-quarters of patients who presented with suspected acute coronary syndrome were safely discharged from ED without hospital admission. Study questions preemptive TEVAR for extended type A dissections Interim results from a single-center study show that preemptive TEVAR may not be necessary for type A aortic dissections. TAVR, SAVR share same infective endocarditis risk Be aware, be careful, and provide appropriate antibiotic prophylaxis, just as surgeons do in SAVR. Moderate aortic stenosis just as deadly as severe AS The current echocardiographic definition of moderate aortic stenosis may greatly underestimate risk. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

8 MIN1 w ago
Comments
Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis

Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk

Smoking and inactivity are the most powerful lifestyle risk factors after an MI Insufficient activity beats out obesity or above-target LDL cholesterol. Ticagrelor monotherapy tops DAPT for high-risk PCI patients TWILIGHT findings support move to shorter dual-antiplatelet therapy. Panel releases guidelines for red meat, processed meat consumption "This assessment may be excessively pessimistic; indeed, we hope that is the case." Remember that preeclampsia has a ‘fourth trimester’ Delivering the baby doesn’t always cure the hypertension. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

8 MIN2 w ago
Comments
Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk

Cardiology dead last as women’s IM subspecialty choice

Cardiology dead last as women’s IM subspecialty choice Women in internal medicine residencies were more likely than men to report that they had never considered cardiology as a career choice. Beta-blockers effective, safe for HFrEF with renal dysfunction Their role is solidified for essentially all such heart failure patients, regardless of their renal function. Heart failure score derived from machine learning predicts risk in diabetes patients Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%. Daily polypill lowers BP, cholesterol in underserved population The regimen’s simplicity and low cost may overcome barriers to treatment. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

7 MIN3 w ago
Comments
Cardiology dead last as women’s IM subspecialty choice

An antiplatelet surprise; Europeans go low in cholesterol guidelines

Prasugrel bests ticagrelor in ACS in surprise findings ISAR-REACT 5 was the first-ever direct head-to-head look at two potent P2Y12 inhibitors in this setting. European cholesterol guidelines push LDL targets below 55 mg/dL PCSK-9 inhibitors are elevated to a top-tier recommendation in very-high-risk patients. Drug doses for heart failure could possibly be halved for women Women reached the highest level of drug efficacy at half the doses of ACE inhibitors or ARBs and beta-blockers. Post-MI angina in stable patients flags high risk The angina finding should immediately influence practice, expert says. For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeCardio

9 MINSEP 20
Comments
An antiplatelet surprise; Europeans go low in cholesterol guidelines

SGLT-2 inhibitors and more practice changing data from ESC 2019

MDedge reporters discuss the latest in practice-changing data from the 2019 annual congress of the European Society of Cardiology in Paris. Join Mitchel L. Zoler, Bruce Jancin, Kari Oakes, and MDedge Cardiology editor Catherine Hackett as they discuss what they reported from the annual meeting.

22 MINSEP 16
Comments
SGLT-2 inhibitors and more practice changing data from ESC 2019

Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment

We introduce a brand new format with Jerome Dwyer, MD, brother of our host, Jim Dwyer, MD, for a new segment that we're calling 'Card Talk' where Dr. Jim and Dr. Jerry talk about the current clinical state of cardiology and take a peek into the future. This week in cardiology news: Survival at ‘overweight’ BMI surpasses ‘normal’Data from more than 142,000 middle-aged people worldwide show those with a BMI of 25-29 outlast those at 20-24. Visceral fat linked to sixfold increase in masked hypertensionThe body mass index trend was not significant. New class of drug safely halved LDL cholesterol in ORION-11Inclisiran potently cut LDL cholesterol by inhibiting the PCSK9 enzyme with biannual injections.

40 MINSEP 13
Comments
Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment

Dapgliflozin transomrs into heart failure drug

DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the drug as a major agent for treating heart failure. New hypertension cases halved with community-wide salt substitution Social marketing principles achieved near-universal salt replacement, village by village, in rural Peru. Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy. In PAD, dropping statins ups death risk 43% Statin adherence saves lives in peripheral arterial disease.

9 MINSEP 6
Comments
Dapgliflozin transomrs into heart failure drug

CV cost of smoking lasts a quarter century

This week in cardiology: PCSK9 inhibition cuts events in very-high-risk groups ODYSSEY OUTCOMES analyses peg prior CABG and polyvascular disease as targets for alirocumab. Cardiovascular cost of smoking may last up to 25 years Past smokers face an elevated cardiovascular risk for up to 25 years after they quit. Impact of climate change on mortality underlined by global study This may be the largest study ever to assess the effects of inhalable particulate matter around the world. HCV coinfection adds to the cardiovascular risk in HIV-infected patients Hepatitis C virus and other injections were independently linked to the risk of having a cardiovascular event in HIV-infected patients. You can contact the MDedge Cardiocast by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.

7 MINAUG 30
Comments
CV cost of smoking lasts a quarter century

Two FDA approvals, smoking impacts CV health for 25 years

TAVR valves now FDA approved for low-risk patients The FDA's decision will expand TAVR access to younger, healthier patients. FDA approves baroreflex activation for advanced HF A phase 4 trial will investigate impact on hospitalizations and mortality. Top line results: Dapagliflozin meets primary endpiont in DAPA-HF AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor. Cardiovascular cost of smoking may last up to 25 years Past smokers face an elevated cardiovascular risk for up to 25 years. You can contact the MDedge Cardiocast by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.

8 MINAUG 23
Comments
Two FDA approvals, smoking impacts CV health for 25 years